We were joined by Tyler Golato and Paul Kohlhaas, co-founders of Molecule and initiators of VitaDAO to talk about how drug discovery and approval currently works, what the status of longevity research is, what role IP plays -- and how all of this could change in the future with DAOs like VitaDAO.
VitaDAO is a decentralized collective funding early stage longevity research. Their mission is to extend human lifespan by researching, financing, and commercializing longevity therapeutics in an open and democratic manner.
We were joined by Tyler Golato and Paul Kohlhaas, co-founders of Molecule and initiators of VitaDAO to talk about how drug discovery and approval currently works, what the status of longevity research is, what role IP plays -- and how all of this could change in the future with DAOs like VitaDAO.
Topics covered in this episode:
Episode links:
Sponsors:
This episode is hosted by Friederike Ernst & Meher Roy. Show notes and listening options: epicenter.tv/403